FORM PTO-1449

U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK

OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.			
U 013589-7	09/890,989			
APPLI	CANT			
Peter David	d DAVIS			
FILING DATE	GROUP			
December 14	1614			

CALLES OF		U.S. P	ATENT DOC	UMENTS					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	3	FILING DATE I NAME APPROPRIATI				
	AA								
	AB			,					
	AC								
	AD								
	AE								
	AF								
	AG								
	АН								
	ΑΙ								
	AJ				•				
	AK				·				
		FOREIG	N PATENT D	OCUMENTS	<u> </u>				
		D0CUMENT	5.47	_	COLDIMBA	TRANSLATION			
	NUMBER		DAT	5 	COUNTRY	YES	NO		
	AL								
	AM								
	AN					_	ļ		
	AO						ļ		
	AP		<u> </u>						
	ОТІ	HER ART (Includ	ing Author, T	itle, Date, Per	tinent Dates, Etc.)				
my	AR	Annex A - Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues: Tozer, Prise, Wilson, Locke, Vojnovic, Stratford, Dennis, Chaplin: Cancer Research 59, 1626-1634, April 1, 1999							
	AS	Annex B - Enhancement of Vascular Targeting by Inhibitors of Nitric Oxide Synthase: Davis, Tozer, Naylor, Thomson, Lewis, Hill: Int. J. Radiation Onocology Biol. Phys. Vol. 54, No. 5 pp. 1532-1536, 2002							
	AT	Annex C - Effect of the tumor vascular damaging agent, ZD6126 on the radioresponse of U97 glioblastoma: Wachsberger, Burd, Marrrero, Daskalakis, Ryan, McCue, Dicker:							
EXAMINER	misool	DATE CONSIDERED 3-20-86							
EXAMINER:	Initial if citation	considered, whether or ce and not considered.	not citation is Include copy	in conformat	nce with MPEP 609; Dra vith next communication	w line through c to applicant.	itation if		